Background: Assessing the targeted node, a biopsy-proven metastatic node marked with a metallic clip before neoadjuvant chemotherapy along with sentinel node dissection improves the evaluation of pathological response in the axillary nodal basin after systemic treatment as compar...
Open access
Research Article10.9734/jammr/2024/v36i45396
Background: Breast cancer incidence is highest in Pakistan among Asian countries. The known risk factors are family history, hormonal exposure, benign proliferative diseases, and high mammographic density which are included in the TyrerCuzick model. The model needs validation stu...
Open access
Research Article10.9734/jammr/2021/v33i2331188
Background: Systemic chemotherapy is the standard of care for patients with metastatic breast cancer, with an undecided role in surgery. Limited data is available for the role of surgery on the overall survival of stage 4 breast cancer regarding luminal subtypes of patients. This...
Open access
Research Article10.9734/jammr/2021/v33i2231167
Background: Even with the advances in the diagnosis and treatment of breast malignancy, to date breast cancer is still the number one cause of death in women in Pakistan. Various researches proved that prolonged inflammatory conditions played a part in progression of malignancy,...
Open access
Research Article10.9734/jammr/2021/v33i1430975
Introduction: Breast cancer is one of the most common malignancies worldwide, with tumor size and axillary lymph node metastasis serving as crucial determinants for staging and prognosis. While sentinel lymph node biopsy (SLNB) is well-established for T1 and T2 breast lesions, it...
Open access
Research Article10.9734/jammr/2024/v36i115643
Introduction: Pathological complete response (pCR) is the most important prognostic factor in determining survival in post-neoadjuvant breast cancer. In this study, we evaluated the pathologic predictors that are associated with pCR in post-neoadjuvant breast cancer. Methods: It...
Open access
Research Article10.9734/jammr/2023/v35i34950
Neoadjuvant systemic therapy previously given for inoperable breast cancer is increasingly being administered in early breast cancer especially in triple negative and HER2 positive molecular subtypes. It is associated with an increased rate of complete pathologic response (PCR) w...
Open access
Research Article10.9734/jammr/2022/v34i331269